logo
logo
Annexon, Inc.

Annexon, Inc.

NASDAQ•ANNX
CEO: Mr. Douglas Love Esq., J.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2020-07-24
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
連絡先情報
1400 Sierra Point Parkway, Building C Suite 200, Brisbane, CA, 94005, United States
650-822-5500
www.annexonbio.com
時価総額
$602.76M
PER (TTM)
-3.6
19.5
配当利回り
--
52週高値
$7.18
52週安値
$1.29
52週レンジ
64%
順位57Top 83.3%
2.4
F-Score
改良版 Piotroski 分析
8年ファンダメンタル
弱い • 2.4 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2018-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%
直近4四半期の推移

EPS

-$0.37+48.00%
直近4四半期の推移

フリーCF

-$52.35M+63.48%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

R&D Expenses Surge 87% Nine-month R&D expenses reached $142.0M, increasing $65.9M (87%) driven by clinical trial advancement and technology transfer.
Liquid Assets $188.7M Available cash and short-term investments totaled $188.7M as of September 30, 2025, funding operations into Q1 2027.
Net Loss Widens Significantly Nine-month net loss increased 77% to $158.4M in 2025, primarily due to increased operating expenses supporting pipeline progression.
ATM Equity Proceeds Raised Sold $13.5M net proceeds from common stock via 2024 ATM program during the nine months ended September 30, 2025.

リスク要因

Substantial Additional Financing Needed Future viability beyond Q1 2027 depends on obtaining necessary capital; failure to secure funding could halt development programs.
Clinical Data Uncertainty High Success hinges on positive Phase 3 results for vonaprument (GA) and tanruprubart (GBS); regulatory acceptance is not assured.
Reliance on Third-Party Manufacturing Complete dependence on external partners for clinical and commercial supply introduces risks regarding quality control and delivery timelines.
Intellectual Property Enforcement Costs Commercial success relies on enforcing IP rights, facing risks from costly litigation and potential patent invalidation challenges.

見通し

GBS MAA Submission Planned Anticipate Marketing Authorization Application (MAA) submission for tanruprubart in GBS to European regulators in January 2026.
GA Phase 3 Data Expected Topline data for the global Phase 3 ARCHER II trial for vonaprument in GA is planned for reporting in the second half of 2026.
Continue High Operating Expenses Expect R&D expenses to increase further while advancing late-stage trials and investing in capabilities to prepare for commercialization.
ANX1502 POC Update 2026 Evaluating ANX1502 in CAD patients; plan to provide profile update upon completion of the ongoing Phase 1 study in 2026.

同業比較

売上高 (TTM)

Alector, Inc.ALEC
$69.05M
+12.3%
Editas Medicine, Inc.EDIT
$46.38M
-24.9%
BioLineRx Ltd.BLRX
$17.25M
-21.6%

粗利益率 (最新四半期)

Korro Bio, Inc.KRRO
100.0%
+0.0pp
Lyell Immunopharma, Inc.LYEL
100.0%
+0.0pp
Editas Medicine, Inc.EDIT
100.0%
+2621.3pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
ANNX$602.76M-3.6-92.3%11.8%
REPL$599.48M-2.1-102.7%23.6%
LYEL$539.17M-1.4-96.7%10.9%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
N/M
売上高の変動が大きい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月2日
|
EPS:-$0.32
|
売上高:-
財務レポート
財務データ
ニュース
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月10日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.37+48.0%
    不明

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月14日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.34+47.8%
    不明

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月12日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.37+76.2%
    不明

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月3日|
    売上高: $0.00+0.0%
    |
    EPS: $-1.01+42.9%
    不明

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月14日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.25-41.9%
    不明

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月12日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.23-51.1%
    不明

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月13日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.21-56.3%
    不明

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月26日|
    売上高: $0.00+0.0%
    |
    EPS: $-1.77+31.9%
    不明